VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test

November 03, 2026

Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to...

Performance

52-Week Range 95.9% below 52-week high

0.1401

0.1452W Low 3.4052W High

1 Week 16.6% below 1-week high

0.141W Low 0.171W High

VivoSim Labs, Inc. - Common Stock (VIVS) traded between $0.14 and $3.40 over the past 52 weeks and last traded at $0.14, 95.9% below its 52-week high. Over the past week it ranged between $0.14 and $0.17.

Past 12 Months

-11.2%

-32.1%

-61.5%

-90.1%

-92.5%

-93.6%

1W -$0.02

1M -$0.07

3M -$0.22

6M -$1.27

YTD -$1.74

1Y -$2.06

VIVS was -93.6% over the past year, -90.1% over six months, -92.5% year to date, -11.2% in the last week.

12 Months vs Market

VIVS

-93.6%

DIA

+10.6%

SPY

+10.2%

QQQ

+7.0%

IWM

+14.2%

Over the past 12 months VIVS returned -93.6% versus DIA (Dow) +10.6%, SPY (S&P 500) +10.2%, QQQ (Nasdaq 100) +7.0% and IWM (Russell 2000) +14.2%.

Volume & Liquidity 0.08× 3-mo avg

Today 213,710 3-mo avg 2.6M

1.2M

995.6K

2.6M

3.1M

YTD

2.3M

1.9M

VIVS most recently traded 213,710 shares against a 3-month average daily volume of 2.6M.

More News

Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch

October 28, 2026

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

October 21, 2026

5 Biotech Stocks’ TCRT, IGC, PDSB, PFAI, Acquisition, Alzheimer’s, Cardio and Cancer Research Milestones

October 13, 2026

4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch

October 07, 2026

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

October 07, 2026

2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus

October 01, 2026

2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!

September 28, 2026

VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs

September 28, 2026

Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside

September 21, 2026

VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem

September 21, 2026

High-Impact Stocks DRK, VIVS, AEMD, GMG in the News

September 17, 2026

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

September 16, 2026

Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter

September 14, 2026

VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials

September 10, 2026

VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity

September 02, 2026

Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now

September 01, 2026

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

September 01, 2026

IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook

September 01, 2026

VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology

August 26, 2026

Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now

August 26, 2026

VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum

August 25, 2026

VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum

August 17, 2026

VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

August 14, 2026